NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-510-8998800
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees70
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."
When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?
NovaBay Pharmaceuticals's stock reverse split before market open on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter. The biopharmaceutical company had revenue of $1.79 million for the quarter. View NovaBay Pharmaceuticals' Earnings History.
When is NovaBay Pharmaceuticals' next earnings date?
What price target have analysts set for NBY?
3 brokerages have issued twelve-month target prices for NovaBay Pharmaceuticals' stock. Their forecasts range from $1.10 to $1.50. On average, they expect NovaBay Pharmaceuticals' share price to reach $1.30 in the next year. This suggests a possible upside of 88.4% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.
What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.
What are Wall Street analysts saying about NovaBay Pharmaceuticals stock?
Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (3/14/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $31M, which includes a discounted cash flow based asset value for Avenova, using 15% discount rate and 2% terminal growth rate." (3/13/2019)
Has NovaBay Pharmaceuticals been receiving favorable news coverage?
Media headlines about NBY stock have been trending negative on Saturday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for NovaBay Pharmaceuticals.
Are investors shorting NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 169,200 shares, a drop of 76.7% from the July 31st total of 725,800 shares. Based on an average daily volume of 2,490,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.5% of the shares of the company are sold short. View NovaBay Pharmaceuticals' Current Options Chain.
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include Circassia Pharmaceuticals (CIR), Equillium (EQ), Pediapharm (PDP), Medicure (MPH), ReNeuron Group (RENE), Promis Neurosciences (PMN), AquaBounty Technologies (AQB), Mereo BioPharma Group (MPH), IntelGenx Technologies (IGX), Orthocell (OCC), 4d Pharma (DDDD), Novoheart (NVH), Verona Pharma (VRP), Zelda Therapeutics (ZLD) and Noxopharm (NOX).
What other stocks do shareholders of NovaBay Pharmaceuticals own?
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the folowing people:
- Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
- Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
- Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)
Who are NovaBay Pharmaceuticals' major shareholders?
NovaBay Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.96%) and Jane Street Group LLC (0.18%). Company insiders that own NovaBay Pharmaceuticals stock include Jacques Bonneau, Mijia Wu and Pharma (Hong Kong) Co Pioneer. View Institutional Ownership Trends for NovaBay Pharmaceuticals.
Which institutional investors are buying NovaBay Pharmaceuticals stock?
How do I buy shares of NovaBay Pharmaceuticals?
Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is NovaBay Pharmaceuticals' stock price today?
One share of NBY stock can currently be purchased for approximately $0.69.
How big of a company is NovaBay Pharmaceuticals?
What is NovaBay Pharmaceuticals' official website?
How can I contact NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.
MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
